Loading stock data…
ALC
$67.90+1.79 (+2.71%)
After Hours$67.90+0.00 (+0.00%)· Last close Jun 9
Alcon Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alcon Inc. in the Healthcare sector is trading at $67.90 with a market capitalization of $31.3B. Wall Street consensus targets $88.52 (15 analysts), implying a +30.4% move over the next 12 months. The stock is currently near its 52-week low of $61.84, remaining 10.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +30.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$67.90
Potential Upside
18.2%
Whystock Fair Value$80.27
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Buy
Mean target$88.52+30.4%
Range$66.00 – $112.00
Fundamentals
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$31.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
38.46
Beta
Defensive asset. Lower volatility than the S&P 500.
0.70
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.53%
ROE
Average efficiency. Growth may require heavy reinvestment.
3.70%
Volume
Today's trading volume
1.35M
Recent News
Reasons to Add Tandem Diabetes Stock to Your Portfolio Right Now
TNDM's pay-as-you-go shift, international expansion and strong liquidity support growth, while macro and reimbursement risks remain.
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Alcon's Surgical and Vision Care units returned to 6% growth in Q1 2026, but tariffs, macro pressure and fierce competition still loom.
Evaluating Alcon (SWX:ALC) After Recent Share Price Weakness And Perceived Valuation Gap
Recent share performance and business snapshot Alcon (SWX:ALC) has drawn attention after a period where the stock is down about 10% over the past month and about 17% over the past 3 months, while the company’s eye care business generated CHF 10,634.0 million in revenue and net income of CHF 819.0 million. See our latest analysis for Alcon. Looking beyond the recent pullback, Alcon’s share price return is down over the year and over multi year periods, while the latest short term recovery...
Does Alcon (SWX:ALC) Offer Opportunity After A 26% One Year Share Price Slide?
If you are wondering whether Alcon stock offers fair value around its recent price, or if the risks are starting to outweigh the potential, this article walks through the key signals to help you answer that for yourself. Over shorter periods the stock has been mixed, up 3.6% over the last week, but down 10.2% over the last month, 16.1% year to date, and 26.1% over the past year, which may have shifted how investors are thinking about both risk and opportunity. Recent coverage has focused on...
Reasons to Retain STE Stock in Your Portfolio for Now
STERIS' Healthcare and AST segments post solid gains and milestones, but FX volatility, tariffs and global macro pressures threaten earnings variability.